CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2016 ESMO Congress
Oncology Conference Multimedia
View more videos >>
Dr. Mirza on Impact of Niraparib in Ovarian Cancer
Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC
Dr. Patrick M. Forde on Neoadjuvant Nivolumab in NSCLC
Oncology Conference Articles
Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer
Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.
Novel HER2-Targeting Antibody-Drug Conjugate Shows Broad Antitumor Activity
A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.
Long-Term Follow-Up Supports Frontline Dabrafenib/Trametinib in Melanoma
Co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.
Niraparib Expected to Change Practice in Ovarian Cancer
The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Streamlined BRCA Testing Program Shows Promise in Ovarian Cancer
An interim analysis of an ongoing study showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.
Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer
Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.
Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer
The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.
Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers
Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.
Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC
Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.
No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy
Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.
Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC
The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.
Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study
First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.
Frontline Cabozantinib Bests Sunitinib in mRCC
Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.
First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer
Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.
Nivolumab Misses PFS Endpoint in First-Line Advanced NSCLC
First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.
Unexpected Benefit Observed From Neoadjuvant Therapy in High-Risk Soft Tissue Sarcoma
A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy.
Adjuvant Sunitinib Extends DFS in High-Risk RCC
Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.
Atezolizumab Significantly Extends Survival in NSCLC
Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.
Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC
Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.
Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval
Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.
Frontline Pembrolizumab Data Is Practice Changing for NSCLC
Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.
Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer
A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.
Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib
The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer
Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.
Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer
Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline
-positive platinum-sensitive, recurrent ovarian cancer.
Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma
Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.
High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer
The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic
mutations showed a durable response to rucaparib.
Neoadjuvant Anti-PD-1 Therapy Active in NSCLC
Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.
Thousands of Melanoma Patients in Europe Not Receiving Novel Agents
Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.
NDA Withdrawn in Melanoma, Promising Phase III Results in Breast Cancer and Ovarian Cancer, and More
FDA Approves Niraparib for Ovarian Cancer
Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer
Efforts Continue to Introduce Immunotherapy Into Earlier NSCLC Settings
Expert Tackles Efficacy of PD-L1 Testing for NSCLC in 2017
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.